The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.10
Bid: 44.10
Ask: 45.90
Change: 0.00 (0.00%)
Spread: 1.80 (4.082%)
Open: 44.10
High: 44.10
Low: 44.10
Prev. Close: 45.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Share Options

25 Jan 2018 11:54

RNS Number : 9419C
Benchmark Holdings PLC
25 January 2018
 

25 January 2018

 

BENCHMARK HOLDINGS PLC("Benchmark" or the "Company")

DIRECTOR SHARE OPTIONS

Benchmark Holdings plc announces that on 24 January 2018, and in accordance with the intention disclosed in its Annual Report and Accounts published on 23 January 2018, options over Ordinary Shares of 0.1 pence each ("Ordinary Shares") were granted to Malcolm Pye, Chief Executive Officer and Mark Plampin, Chief Financial Officer under the Company Share Option Plan (CSOP) in lieu of a cash bonus in respect of the 2017 financial year.

Options over a total of 500,000 Ordinary Shares were granted to Malcolm Pye and options over a total of 400,000 Ordinary Shares were granted to Mark Plampin. Following this grant, Malcolm Pye remains interested in 15,145,686 Ordinary Shares and holds options over a total of 500,000 Ordinary Shares in the Company, representing approximately 2.90% and 0.10% of Benchmark's existing issued share capital respectively. Mark Plampin remains interested in 536,686 Ordinary Shares and holds options over a total of 524,585 Ordinary Shares in the Company, representing approximately 0.10% and 0.10% of Benchmark's existing issued share capital respectively.

The options granted have a vesting period of three years, may be exercised up to the tenth anniversary of grant, have an exercise price of 69.5 pence per Ordinary Share, and are not subject to performance criteria.

 

Notification and public disclosure of a transactions by a persons discharging managerial responsibilities: 

 

Details of the person discharging managerial responsibilities / person closely associated 

 

a) 

 

Name 

 

Malcolm Pye

 

Reason for the notification 

 

a) 

 

Position/status 

 

Executive Director 

b) 

 

Initial notification/Amendment 

 

Initial

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

 

a) 

 

Name

 

Benchmark Holdings plc

b) 

 

LEI 

n/a

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a) 

 

Description of the financial instrument, type of instrument 

Identification code 

 

0.1p ordinary shares

ISIN: GB00BGHPT808 

b) 

 

Nature of the transaction 

 

Issue of share options under Company Share Option Plan (CSOP)

c) 

 

Price(s) and volume(s) 

 

 

Exercise price

 

Volume(s)

69.5 pence

500,000

d) 

 

Aggregated information

- Aggregated volume 

- Price 

 

Volume: 500,000

Price: Nil

e) 

 

Date of the transaction 

 

24 January 2018

f) 

 

Place of the transaction 

 

AIM Market, London Stock Exchange

 

 

 

 

Details of the person discharging managerial responsibilities / person closely associated 

 

a) 

 

Name 

 

Mark Plampin 

 

Reason for the notification 

 

a) 

 

Position/status 

 

Executive Director 

b) 

 

Initial notification/Amendment 

 

Initial

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

 

a) 

 

Name

 

Benchmark Holdings plc

b) 

 

LEI 

n/a

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a) 

 

Description of the financial instrument, type of instrument 

Identification code 

 

0.1p ordinary shares

ISIN: GB00BGHPT808 

b) 

 

Nature of the transaction 

 

Issue of share options under Company Share Option Plan (CSOP)

c) 

 

Price(s) and volume(s) 

 

 

Exercise price

 

Volume(s)

69.5 pence

400,000

d) 

 

Aggregated information

- Aggregated volume 

- Price 

 

Volume: 400,000

Price: Nil

e) 

 

Date of the transaction 

 

24 January 2018

f) 

 

Place of the transaction 

 

AIM Market, London Stock Exchange

 

 

 

ENDS

 

 

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

Ivonne Cantu, Investor Relations Director

Rachel Aninakwah, Communications

Numis

Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

MHP

Katie Hunt / Reg Hoare / Alistair de Kare-Silver

Tel: 020 3128 8742 07551 170 451

benchmark@mhpc.com

 

Notes to Editors:

Benchmark challenges the status quo in aquaculture. Since 2000, Benchmark has consistently worked to build a technology-rich platform in the areas of genetics, nutrition, animal health and knowledge services, to serve its customers, helping them take control of their biological environment to improve yield and efficiency in a sustainable way. 

The Company has leading positions in its core markets and established R&D, manufacturing and distribution capabilities to serve all the major aquaculture markets. Benchmark operates in 27 countries in five continents and as at 30 September 2017, it employed 950 people. 

For further information on Benchmark please visit www.benchmarkplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBAMBTMBATBJP
Date   Source Headline
30th Nov 20187:00 amRNSTotal Voting Rights
27th Nov 20187:00 amRNSSuccessful defence of patent infringement in Asia
7th Nov 20187:00 amRNSTrading Statement
31st Oct 20187:00 amRNSTotal Voting Rights
23rd Oct 20184:55 pmRNSHolding(s) in Company
22nd Oct 20185:52 pmRNSHolding(s) in Company
10th Oct 20182:53 pmRNSDIRECTOR DEALINGS
3rd Oct 20187:00 amRNSAcquisition and Issue of Equity
2nd Oct 20187:00 amRNSAppointment of Chief Scientific Officer
28th Sep 20187:00 amRNSTotal Voting Rights
21st Sep 20187:00 amRNSBlock listing Interim Review
12th Sep 20187:00 amRNSBlock Admission Application
10th Sep 20187:00 amRNSCommencement of salmon egg production in Salten
30th Aug 20187:00 amRNSTotal Voting Rights
30th Jul 20187:00 amRNSTotal Voting Rights
2nd Jul 20187:00 amRNSAppointment of Executive Director
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 20184:01 pmRNSHolding(s) in Company
22nd Jun 20184:31 pmRNSHolding(s) in Company
22nd Jun 20187:00 amRNSDIRECTOR DEALINGS
19th Jun 20184:06 pmRNSUpdate on Joint Venture and Placing
19th Jun 20187:00 amRNSInterim Results
8th Jun 20187:00 amRNSJoint Venture, Placing and Trading Update
31st May 20187:00 amRNSTotal Voting Rights
8th May 20187:00 amRNSAppointment of Chairman
30th Apr 201812:23 pmRNSTotal Voting Rights
9th Apr 201811:14 amRNSHolding(s) in Company
5th Apr 20183:58 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSTotal Voting Rights
27th Mar 20187:00 amRNSBenchmark hosts Capital Markets Day today
21st Mar 20187:00 amRNSBlock listing six monthly return
8th Mar 20181:37 pmRNSResult of AGM
7th Feb 20189:05 amRNSDirector Dealings
31st Jan 20187:00 amRNSBoard Succession
31st Jan 20187:00 amRNSTotal Voting Rights
25th Jan 201811:54 amRNSDirector Share Options
24th Jan 20183:17 pmRNSHolding(s) in Company
24th Jan 20181:01 pmRNSDirector Dealings
24th Jan 20187:00 amRNSPosting of Annual Report & Notice of AGM
23rd Jan 20187:08 amRNSFinal Results
19th Jan 20184:40 pmRNSSecond Price Monitoring Extn
19th Jan 20184:35 pmRNSPrice Monitoring Extension
5th Jan 20184:19 pmRNSHolding(s) in Company
4th Jan 20184:41 pmRNSSecond Price Monitoring Extn
4th Jan 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20177:00 amRNSCommercial scale field trial of sea lice treatment
7th Dec 20177:00 amRNSBenchmark participates in gene editing research
5th Dec 20177:00 amRNSTrading Update and Notice of Results
8th Nov 20177:00 amRNSDevelopment of disease-resistant shrimp

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.